Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01896479
Title	A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)
Acronym	EXAMINER
Recruitment	Active, not recruiting
Gender	both
Phase	FDA approved
Variant Requirements	Yes
Sponsors	Exelixis
Indications	medullary thyroid carcinoma
Therapies	Cabozantinib
Age Groups:	senior \| adult
Covered Countries	SWE \| ROU \| POL \| NLD \| ITA \| ISR \| HUN \| HRV \| FRA \| ESP \| CAN \| AUS